101 studies found for:    mdv3100 | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Drug: Enzalutamide;   Drug: Carboplatin;   Drug: Paclitaxel
2 Not yet recruiting A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Condition: Metastatic Castration-Resistant Prostate Cancer
Interventions: Drug: ZEN003694;   Drug: Enzalutamide
3 Recruiting A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
Condition: Advanced Hepatocellular Carcinoma
Interventions: Drug: enzalutamide;   Drug: placebo
4 Recruiting Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Conditions: Hormone Sensitive Prostate Cancer;   Prostate Cancer;   Cancer of the Prostate
Interventions: Drug: Enzalutamide;   Drug: Placebo;   Drug: Leuprolide
5 Recruiting Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Enzalutamide
Conditions: Hormone-Resistant Prostate Cancer;   Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Other: Cytology Specimen Collection Procedure;   Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis
6 Not yet recruiting Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: Paclitaxel
7 Not yet recruiting Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
Condition: Cancer
Interventions: Drug: Afuresertib;   Drug: Enzalutamide;   Drug: Abiraterone;   Drug: Prednisone
8 Recruiting Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Conditions: Nonmetastatic Castration-Resistant Prostate Cancer;   Prostate Cancer;   Cancer of the Prostate
Interventions: Drug: Enzalutamide;   Drug: Placebo
9 Recruiting Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Biomarker Analysis;   Drug: Enzalutamide;   Other: Pharmacological Study;   Drug: Taselisib
10 Recruiting RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study)
Condition: Prostate Cancer
Interventions: Drug: Testosterone cypionate;   Drug: Testosterone Enanthate;   Drug: Abiraterone acetate;   Drug: Enzalutamide
11 Recruiting Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Dexamethasone;   Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
12 Recruiting Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostatic Adenocarcinoma;   Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis
13 Recruiting Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
Condition: Castration Resistant Metastatic Prostate Cancer
Interventions: Drug: Testosterone cypionate;   Drug: Enzalutamide;   Drug: Testosterone Enanthate
14 Recruiting Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
Condition: Adenocarcinoma of the Prostate
Interventions: Drug: Enzalutamide;   Radiation: SRT
15 Recruiting LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: bicalutamide;   Procedure: orchiectomy;   Drug: leuprolide acetate;   Drug: goserelin acetate;   Other: laboratory biomarker analysis
16 Recruiting Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Cabazitaxel;   Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prednisone
17 Recruiting A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
Conditions: Prostate Carcinoma Metastatic to the Bone;   Castration Resistant Prostate Cancer
Intervention: Drug: Enzalutamide
18 Recruiting Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Condition: Castration-resistant Prostate Cancer
Interventions: Drug: Crizotinib;   Drug: Enzalutamide
19 Recruiting Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   Stage IV Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: Ribociclib
20 Recruiting Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: LY2157299

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years